Scott T. Tagawa, MD, Talks Current Initiatives in Prostate Cancer

Scott T. Tagawa, MD, spoke about potential approvals in the coming year for prostate cancer.

At the15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, CancerNetwork® spoke with Scott T. Tagawa, MD, from Weill Cornell Medicine in New York, about current initiatives in prostate cancer. He mentioned nearing approval of Lutetium-177 (177Lu-PSMA-617) and how it would help to expand upon treatment options for patients with prostate cancer.


Translation from research to therapeutics is going to have a significant impact on the lives of patients with advanced prostate cancer. This happens to be PSA [prostate specific antigen],–targeted radionucleotides with the expected 2022 approval of 177Lu-PSMA-617. That’s going to be a near-term approval with a new class of drugs. Hopefully we can expand upon that to make [treatment] even better by using it for earlier patient populations in combinations or in better patient selections. That’s the possibility.

For a major advance in the future, maybe not in 2022 but in the future, are more effective immunotherapeutics. It does not appear [to be ready for the real-world setting], other than in very select patients, at least not [with PD-1 or PD-L1 inhibitors]. There are a number of other immunotherapeutics targeted typically against cell surface proteins, such as PSMA [prostate-specific membrane antigen] or PSCA [prostate stem cell antigen]. There’s also STEEP1, DLL3, and a number of other cell service targets, [that can be targeted with] either bispecifics, or BiTEs, or with CAR T cell therapies. I don’t think that’s ready for prime time today. I’m quite hopeful that at least a substantial subset [of patients are] able to handle these drugs. We might not just see an improvement for some number of months, but some very durable responses or maybe even cures with some of these instruments. That’s what I’m hoping for in the future.

Related Videos
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Lenvatinib plus pembrolizumab appears to be the best option for patients with refractory metastatic renal cell carcinoma who are progressing on immunotherapy combinations or are lenvatinib naïve.
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
Expert cardiologist
Expert urologist
Related Content